TELA Bio Management

How has Antony Koblish's remuneration changed compared to TELA Bio's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$47m
Sep 30 2023	n/a	n/a	-US$44m
Jun 30 2023	n/a	n/a	-US$44m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$2m	US$566k	-US$44m
Sep 30 2022	n/a	n/a	-US$43m
Jun 30 2022	n/a	n/a	-US$40m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$2m	US$538k	-US$33m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$806k	US$479k	-US$29m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$29m
Dec 31 2019	US$2m	US$403k	-US$30m
Sep 30 2019	n/a	n/a	-US$32m
Jun 30 2019	n/a	n/a	-US$30m
Mar 31 2019	n/a	n/a	-US$28m
Dec 31 2018	US$569k	US$375k	-US$30m

Vergütung im Vergleich zum Markt: AntonyDie Gesamtvergütung ($USD2.12M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD738.70K).

Entschädigung vs. Einkommen: AntonyDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

CEO

Antony Koblish (57 yo)

12yrs

Tenure

US$2,118,260

Compensation

Mr. Antony Koblish is an Operating Partner of 1315 Capital LLC. Mr. Koblish serves as the President, Director and Chief Executive Officer of TELA Bio, Inc. since April 2012, which he co-founded in April 20...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Antony Koblish	Co-founder	12yrs	US$2.12m	0.87% $ 1.1m
Roberto Cuca	CFO & COO	2.6yrs	US$1.02m	0.16% $ 199.4k
Paul Talmo	Chief Technology Officer	no data	US$858.26k	0.12% $ 150.3k
Megan Smeykal	VP, Corporate Controller	2.9yrs	no data	0.033% $ 40.9k
D. Ocasio	General Counsel & Corporate Secretary	2yrs	no data	no data
Jennifer Armstrong	Senior Vice President of Human Resources	2.3yrs	no data	no data
Gregory Firestone	Chief Business Officer	no data	no data	0.21% $ 254.7k
Michael Leonard	Senior Vice President of Technical Operations	2.3yrs	no data	no data
Peter Murphy	Chief Commercial Officer	4.3yrs	US$936.76k	0.055% $ 68.2k
Louisa Smith	Investor Relations Contact Officer	no data	no data	no data

2.6yrs

Average Tenure

53yo

Average Age

Erfahrenes Management: TELADas Führungsteam des Unternehmens gilt als erfahren (2.6 Jahre durchschnittliche Betriebszugehörigkeit).

Board Members

Name	Position	Tenure	Compensation	Ownership
Antony Koblish	Co-founder	12yrs	US$2.12m	0.87% $ 1.1m
Vincent Burgess	Independent Director	11.3yrs	US$99.83k	0.032% $ 40.2k
Federica O'Brien	Independent Director	4.4yrs	US$104.83k	0.013% $ 15.8k
Douglas Evans	Independent Chairman of the Board	4yrs	US$132.33k	0.013% $ 15.8k
Lisa Colleran	Independent Director	4yrs	US$104.83k	0.013% $ 15.8k
Kurt Azarbarzin	Independent Director	5.4yrs	US$92.33k	0.013% $ 15.8k

4.9yrs

Average Tenure

60yo

Average Age

Erfahrener Vorstand: TELADie Vorstandsmitglieder gelten als erfahren (4.6 Jahre durchschnittliche Amtszeit).

TELA Bio Management

Management criteria checks 2/4

Key information

Recent management updates

John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc

Insufficient new directors

CFO & COO recently bought US$83k worth of stock

TELA Bio, Inc., Annual General Meeting, Jun 01, 2022

TELA Bio, Inc. Appoints Taylor Ocasio as General Counsel

High number of new directors

Recent updates

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

TELA Bio, Inc. Announces U.S. Commercial Launch of LIQUIFIX

Full year 2023 earnings released: US$2.04 loss per share (vs US$2.72 loss in FY 2022)

Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

TELA Bio, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Consensus EPS estimates fall by 215%

TELA Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased by 18% to US$14.40

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

TELA Bio, Inc. to Report Q3, 2023 Results on Nov 09, 2023

TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc

TELA Bio, Inc. Announces U.S. Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Consensus EPS estimates upgraded to US$0.57 loss

Second quarter 2023 earnings: EPS exceeds analyst expectations

TELA Bio, Inc. Reaffirms Revenue Guidance for Full Year 2023

Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

TELA Bio, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Tela Bio, Inc. Reaffirms Earnings Guidance for the Full Year 2023

Insufficient new directors

Consensus EPS estimates fall by 13%, revenue upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

TELA Bio Announces U.S. Commercial Launch of NIVIS Fibrillar Collagen Pack

Price target decreased to US$17.40

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$17.40

TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022

TELA Bio, Inc. to Report Q3, 2022 Results on Nov 09, 2022

TELA Bio, Inc. Announces Publication of 24-Month Bravo Study Results Demonstrating Benefits of Ovitex(R) Reinforced Tissue Matrix in Hernia Repair

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Consensus forecasts updated

TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $32 million.

Tela Bio prices $32M common stock offering

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022

Tela Bio, Inc. Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs

TELA Bio, Inc. to Report Q2, 2022 Results on Aug 10, 2022

CFO & COO recently bought US$83k worth of stock

TELA Bio, Inc. Provides Revenue Guidance for the Fiscal Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

TELA Bio, Inc. Announces Revenue Guidance for the Full Year 2022

TELA Bio, Inc., Annual General Meeting, Jun 01, 2022

TELA Bio, Inc. Appoints Taylor Ocasio as General Counsel

TELA Bio, Inc. Announces U.S. Commercial Launch of SiteGuard™ No Rinse Antimicrobial Solution

TELA Bio - Follow Up With Management

High number of new directors

Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 3Q 2020)

Our First Look At TELA Bio

TELA Bio Plugging Away

TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique

Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 2Q 2020)

TELA Bio, Inc. Provides Earnings Guidance for the Full Year 2021

High number of new directors

TELA Bio, Inc.(NasdaqGM:TELA) dropped from Russell 3000E Index

Independent Director Adele Oliva has left the company

Chief Financial Officer Nora Brennan has left the company

TELA Bio (TELA) Investor Presentation - Slideshow

TELA Bio, Inc. Initiates Bravo II Study of Ovitex for the Robotic Repair of Ventral Hernias

TELA Bio, Inc. Provides Revenue Guidance for the Full Year of 2021

First quarter 2021 earnings released: US$0.56 loss per share (vs US$0.63 loss in 1Q 2020)

Consensus revenue estimates fall to US$28.9m

Bearish: Analysts Just Cut Their TELA Bio, Inc. (NASDAQ:TELA) Revenue and EPS estimates

Full year 2020 earnings released: US$2.23 loss per share (vs US$17.10 loss in FY 2019)

TELA Bio, Inc. Provides Revenue Guidance for the Full Year of Fiscal 2021

TELA Bio, Inc. Announces 12-Month Analysis from BRAVO Study of OviTex® for Ventral Hernia Repair

TELA Bio, Inc. to Report Q4, 2020 Results on Mar 24, 2021

Health Check: How Prudently Does TELA Bio (NASDAQ:TELA) Use Debt?